Keros Therapeutics (KROS) Shares Outstanding (2019 - 2026)

Keros Therapeutics (KROS) has 7 years of Shares Outstanding (Entity) data on file, last reported at $40.7 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) changed 0.29% year-over-year to $40.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $40.7 million (changed 0.29% YoY) and the FY2025 annual result came in at $40.7 million, changed 0.29% from the prior year.
• Shares Outstanding (Entity) was little changed at $40.7 million in Q4 2025, from $40.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $40.7 million in Q4 2025 to a low of $23.3 million in Q1 2021.
• A 5-year average of $31.6 million and a median of $29.7 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) soared 833.97% — and 2025, when it climbed 0.29%.
• Tracing KROS's Shares Outstanding (Entity) over 5 years: stood at $24.0 million in 2021, then rose by 14.88% to $27.5 million in 2022, then increased by 15.6% to $31.8 million in 2023, then rose by 27.37% to $40.6 million in 2024, then grew by 0.29% to $40.7 million in 2025.
• The last three Shares Outstanding (Entity) figures came in at $40.7 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025), per Business Quant data.